JAC Advance Access originally published online on November 14, 2005
Journal of Antimicrobial Chemotherapy 2006 57(1):146-149; doi:10.1093/jac/dki413
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital
1 Laboratoire de Bactériologie-Virologie-Hygiène, CHU Dupuytren, EA 3175, Limoges, France; 2 Department of Microbiology, University of Bristol, Bristol, UK; 3 AB BIODISK, Solna, Sweden
Received 20 April 2005; returned 15 June 2005; revised 7 October 2005; accepted 18 October 2005
* Corresponding author. Tel: +33-555-05-63-48; Fax: +33-555-05-67-22; E-mail: fabien.garnier{at}unilim.fr
Objectives: Glycopeptides are the drugs of choice to treat infections due to methicillin-resistant Staphylococcus aureus, but since 1995, glycopeptide-intermediate S. aureus (GISA) and heterogeneous GISA (hGISA) have been reported worldwide. Detection of reduced susceptibility to glycopeptides in S. aureus is very difficult in a routine clinical laboratory. The aim of this study was to investigate the prevalence of hGISA/GISA strains using a three-step approach during a 1 year period.
Methods: The following algorithm was adopted: (i) brain heart infusion agar with 4 mg/L teicoplanin was used to screen S. aureus strains for reduced susceptibility to glycopeptides; (ii) for each agar screen-positive strain, an Etest macromethod using modified cut-off values (vancomycin and teicoplanin 
4 mg/L) was used to detect potential hGISA/GISA; and (iii) the population analysis profile (PAP) method was finally used to confirm the hGISA/GISA phenotype.
Results: In total, 2300 strains of S. aureus were screened and 255 (11%) were categorized as hGISA with the PAP method, whereas no GISA strains were detected. Standard MIC values and current MIC breakpoints could not discriminate the hGISA/GISA phenotype from glycopeptide-susceptible S. aureus. Thus laboratories using currently standardized MIC methods cannot be expected to detect S. aureus strains that may exhibit reduced susceptibility to glycopeptides. Molecular typing by PFGE revealed that 238 strains belonged to the same clone.
Conclusions: A clonal hGISA strain has disseminated within our hospital. The method described in this study has to be further investigated to see if it is applicable to other S. aureus strains.
Keywords: glycopeptide resistance , S. aureus , Etest macromethod , population analysis profile method
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. J. Adam, L. Louie, C. Watt, D. Gravel, E. Bryce, M. Loeb, A. Matlow, A. McGeer, M. R. Mulvey, A. E. Simor, et al. Detection and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006 Antimicrob. Agents Chemother., February 1, 2010; 54(2): 945 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Howden, J. K. Davies, P. D. R. Johnson, T. P. Stinear, and M. L. Grayson Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications Clin. Microbiol. Rev., January 1, 2010; 23(1): 99 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kosowska-Shick, C. Clark, G. A. Pankuch, P. McGhee, B. Dewasse, L. Beachel, and P. C. Appelbaum Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4217 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Leonard, C. Vidaillac, and M. J. Rybak Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2928 - 2933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Leonard, K. L. Rossi, K. L. Newton, and M. J. Rybak Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides J. Antimicrob. Chemother., March 1, 2009; 63(3): 489 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Leonard and M. J. Rybak Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations J. Antimicrob. Chemother., January 1, 2009; 63(1): 155 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kosowska-Shick, L. M. Ednie, P. McGhee, K. Smith, C. D. Todd, A. Wehler, and P. C. Appelbaum Incidence and Characteristics of Vancomycin Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus at Hershey Medical Center Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4510 - 4513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Rybak, S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sadar, and R. N. Jones Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007) J. Clin. Microbiol., September 1, 2008; 46(9): 2950 - 2954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Maor, G. Rahav, N. Belausov, D. Ben-David, G. Smollan, and N. Keller Prevalence and Characteristics of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Bacteremia in a Tertiary Care Center J. Clin. Microbiol., May 1, 2007; 45(5): 1511 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Credito, G. Lin, and P. C. Appelbaum Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill Methodology Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1504 - 1507. [Abstract] [Full Text] [PDF]
|
|